[Clinical trial of cisplatin in the treatment of ovarian carcinoma]

Cisplatin (cis-diamminedichloroplatinum) was administered to 20 patients with histologically proven ovarian cancer. Ten of 20 patients were evaluable. They consisted of 1 patient by single use and 9 by combined use. The dose of cisplatin in single administration was 50 mg/m2, and the schedule for combined administration was as follows: cisplatin (50mg/m2, i.v. day 1), adriamycin (40 mg/m2, i.v. day 1), cyclophosphamide (350 mg/m2, i.v. day 1) and 5-FU (350 mg/m2, i.v. day 1-5). This was repeated every three weeks. The side effects of cisplatin and in its combination use were relatively severe. All of 20 patients showed severe nausea and vomiting, but fortunately there were no signs of hepatotoxicity, bone marrow or renal impairments during these courses. As the result, according to the response criteria of Koyama-Saito's group, out of 10 evaluable patients, the response rate consisting of partial and complete responses was 50% (CR: 3 cases, RP: 2 cases). It is shown that cisplatin is effective and useful in chemotherapy for the patients with ovarian carcinoma.